Information for Healthcare Professionals
FORCE supports healthcare professionals
If you're a healthcare professional caring for individuals and families affected by hereditary cancer, FORCE has evidence-informed tools, education and support resources to facilitate shared decision-making, and compassionate, informed care to help.
Help Your Patients Find Support
FORCE support programs include virtual community meetings, trained guidance from peer navigators and community message boards. We offer your patients multiple ways to connect with others in a safe, supportive environment. Download our flyer with all our support programs.
Support Meetings & Events
FORCE's Support Meetings and Events Calendar provides details on upcoming support meetings, webinars and partner events.
1 to 1 Support & Navigation
FORCE's Peer Navigation Program connects those seeking support with a trained peer navigator who shares a similar experience.
Spotlight
Looking for the latest guidelines?
FORCE provides gene-specific summaries on cancer risk, screening, prevention and treatment guidelines, and resources for individuals with inherited cancer risk.
Customizable Resources
Add your logo and contact info to FORCE materials
FORCE’s resource center allows you to personalize FORCE publications and genetic test result disclosure letters with your contact information and logo for printing or sharing on demand. We also provide links and QR codes to curated content for specific genes, which you can use within your own materials.
Insurance Coverage & Appeals
Find information on insurance coverage and reimbursement for health insurance appeals. Our customizable insurance appeal letters are designed to help you and your patients quickly appeal insurance denials.
Find Research Studies Enrolling People with Inherited Mutations
Use our search and enroll tool to connect your patients to the latest cancer prevention, treatment and quality-of-life studies enrolling people with or at high risk for hereditary cancers.
Phase 2 study comparing talazoparib with or without Enzalutamide in patients with metastatic castration-resistant prostate cancer and an HRR mutation after progression on Abiraterone Acetate or Darolutamide
This study tests whether COM701 (an anti‑PVRIG immunotherapy) given every 3 weeks as maintenance can delay cancer growth after a good response to platinum chemotherapy. Adults with relapsed platinum‑sensitive ovarian, fallopian tube, or primary peritoneal...
FIT Testing for Colorectal Cancer Screening in People with Lynch Syndrome
People with Lynch syndrome currently rely on regular colonoscopies to screen for colorectal cancer. Researchers are studying whether a simple stool-based test called the fecal immunochemical test (FIT) can help identify people who may need...
Go Behind the Headlines
Force's XRAY program shares easy-to-understand information on the latest cancer research.
Study : Some people with recurrent ovarian cancer have long-lasting benefit from PARP inhibitors
PARP inhibitors are medicines used for some people with ovarian cancer as maintenance therapy after treatment. A new study looked at people whose cancer did not worsen for at least 5 years after starting a...
Study : BRCA mutations may improve pembrolizumab response in early TNBC
The BRCAPATH study looked at people with early-stage triple-negative breast cancer (TNBC). Participants received chemotherapy alone or chemotherapy plus the immunotherapy drug Keytruda (pembrolizumab) before surgery. People with a BRCA mutation, particularly those with a...
Study : Combination maintenance therapy may benefit some people with metastatic pancreatic cancer
The phase 2 POLAR trial tested maintenance therapy with Keytruda (pembrolizumab) and Lynparza (olaparib) in metastatic pancreatic cancer patients whose disease had not worsened after platinum-based chemotherapy. Maintenance therapy is treatment given after initial treatment...
Quickly share FORCE resources with just a few clicks!
FORCE’s Healthcare Provider Toolkit makes it easy to distribute resources across your favorite social media platforms.